# US Metagenomic Sequencing Market > US Metagenomic Sequencing Market Research Report: Size, Share, Trend Analysis By Product & Service (Reagents and Consumables, Instruments, Services) and By Technology (Shotgun Metagenomic Sequencing, 16s rRNA Sequencing, Whole Genome Sequencing and De Novo Assembly, Metatranscriptomic) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 14.99% - **2024:** $ 163.2 Million - **2025:** $ 187.66 Million - **2035:** $ 758.53 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), BGI Genomics (CN), Qiagen (DE), Roche (CH), PerkinElmer (US), Agilent Technologies (US), Oxford Nanopore Technologies (GB) **Report ID:** MRFR/LS/18432-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-metagenomic-sequencing-market-19979 --- ## Market Summary ## **US Metagenomic Sequencing Market Overview** As per MRFR analysis, the US Metagenomic Sequencing Market Size was estimated at 139.2 (USD Million) in 2023. The US Metagenomic Sequencing Market Industry is expected to grow from 163.2(USD Million) in 2024 to 905 (USD Million) by 2035. The US Metagenomic Sequencing Market CAGR (growth rate) is expected to be around 16.85% during the forecast period (2025 - 2035). ### **Key US Metagenomic Sequencing Market Trends Highlighted** The US Metagenomic Sequencing Market is experiencing several important trends driven by advancements in technology and the increasing demand for precision medicine. One key market driver is the rising prevalence of infectious diseases, coupled with the need for rapid and accurate diagnostic tools. This has led to greater investment in research and development, as well as collaborations between public health authorities and private companies. Additionally, the growing emphasis on microbiome research is creating opportunities for applications in various fields, including pharmaceuticals, agriculture, and environmental monitoring. Recent trends reflect an increasing adoption of metagenomic sequencing in clinical settings, particularly for identifying pathogens in complex samples where traditional culture methods may fail. The US government has been actively supporting initiatives to enhance bioinformatics infrastructure which is crucial for analyzing vast amounts of sequencing data. Furthermore, the integration of artificial intelligence and machine learning in data analysis is streamlining research processes and enhancing the precision of results. Opportunities within the US market include expanding applications of metagenomic sequencing beyond clinical diagnostics to include personalized medicine and the development of novel therapeutics targeting the microbiome. The rising awareness and adoption of personalized healthcare approaches among the US population can propel further growth in this domain. Regulatory support from institutions like the FDA is also enabling the approval of innovative metagenomic technologies at a faster pace. Overall, the dynamic intersection of technology, healthcare needs, and regulatory frameworks is shaping a vibrant landscape for the US Metagenomic Sequencing Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Metagenomic Sequencing Market Drivers** #### **Growing Demand for Personalized Medicine** The US Metagenomic Sequencing Market Industry is experiencing an increasing demand for personalized medicine, driven by the rising awareness of genomics and its applications in treatment customization. According to a report by the National Institutes of Health (NIH), personalized medicine is projected to significantly enhance patient outcomes. As of 2022, the National Cancer Institute reported that roughly 1.9 million new cancer cases were diagnosed in the US, emphasizing the need for targeted therapies that can be determined through advanced sequencing technologies. This reflects a broader trend toward precision health strategies, which could lead to a rise in the adoption of metagenomic sequencing capabilities to tailor treatments. Research and Development investment from top biopharmaceutical companies, such as Amgen and Gilead Sciences, is also contributing to this growth, pushing the boundaries of how cancer and other diseases can be treated. #### **Increasing Research and Development Activities** The US [Metagenomic Sequencing Market](../../../reports/metagenomic-sequencing-market-5598) Industry is benefiting from heightened Research and Development activities in biotechnology and pharmaceuticals. The US government has invested heavily in genomics research, with the Department of Health and Human Services announcing funding of over USD 1 billion for such initiatives in 2023. This inflow of funding is expected to accelerate innovation and application of metagenomic sequencing technologies. Moreover, organizations like the Broad Institute and Stanford University are conducting extensive R&D in metagenomics, which not only enhances scientific knowledge but also drives available commercial applications, thereby facilitating market growth within the US. #### **Rising Awareness of Infectious Disease Diagnostics** There is an increasing awareness of the importance of infectious disease diagnostics in the US, significantly impacting the US Metagenomic Sequencing Market Industry. The Centers for Disease Control and Prevention (CDC) reported that infectious diseases account for approximately 3 million hospitalizations annually in the US. With the growing threat of emerging infectious diseases, the demand for rapid and accurate diagnostic methods utilizing metagenomic sequencing is expected to rise. This is further underscored by the impact of the Covid-19 pandemic, which has spotlighted the importance of dynamic and rapid pathogen detection capabilities in public health strategies, driving investments from organizations like Illumina and Thermo Fisher Scientific into innovative sequencing solutions. ## **US Metagenomic Sequencing Market Segment Insights** ### **Metagenomic Sequencing Market Product & Service Insights** The US Metagenomic Sequencing Market is witnessing significant evolution within its Product and Service segment, which encompasses essential components such as Reagents and Consumables, Instruments, and Services. Reagents and Consumables remain critical to the market, as they provide the necessary materials for sample processing and analysis. The importance of high-quality reagents is underscored by their direct impact on the accuracy and reliability of sequencing results, making them a crucial aspect of successful metagenomic studies. Instruments play a pivotal role in advancing the capabilities of metagenomic sequencing, as innovative technologies facilitate higher throughput and improved data generation efficiency. As the need for comprehensive genomic data continues to rise in research and clinical applications, cutting-edge instrumentation is poised to dominate the market landscape, driving further advancements in metagenomics. Services within this segment are also gaining traction, providing essential support such as data analysis, bioinformatics, and project consultation, which assist researchers and institutions in navigating the complexities of metagenomic data interpretation. The demand for specialized services highlights the growing reliance on expert knowledge in the field, as well as the increasing importance of collaboration between service providers and researchers. Collectively, these components of the Product and Service segment not only address current market needs but also contribute to the ongoing expansion and growth within the US Metagenomic Sequencing Market, reinforcing the sector’s potential in diverse applications ranging from environmental studies to human health investigations. As the landscape changes, the continuous improvement in technologies and offerings will pave the way for enhanced research capabilities and new opportunities, further solidifying the significance of these elements in the overall market dynamics. Through such advancements, this segment plays an integral role in shaping the future of genomic research and personalized medicine in the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Metagenomic Sequencing Market Technology Insights** The US Metagenomic Sequencing Market, particularly in the Technology segment, plays a crucial role in advancing our understanding of microbial diversity and functionality. Techniques such as Shotgun Metagenomic Sequencing allow for comprehensive analyses of complex microbial communities, making it essential for environmental monitoring and clinical diagnostics. Meanwhile, 16s rRNA Sequencing stands out for its precision in identifying and classifying bacteria, serving as a foundational method in both research and clinical settings. Moreover, Whole Genome Sequencing and De Novo Assembly are pivotal in unraveling the genomes of various organisms, leading to significant discoveries in genomics and microbiomics. The Metatranscriptomic approach further enhances this by providing insights into gene expression within microbial communities, which has implications for health and disease management. With these technologies, the US Metagenomic Sequencing Market is positioned to enrich our understanding of microbial ecosystems, contributing significantly to fields such as healthcare, agriculture, and environmental science. Overall, these techniques drive innovation while offering vast opportunities for research, product development, and applications across numerous industries. ## **US Metagenomic Sequencing Market Key Players and Competitive Insights** The competitive landscape of the US Metagenomic Sequencing Market is characterized by rapid advancements in technology and a growing emphasis on personalized medicine. As researchers and clinicians increasingly recognize the importance of understanding complex microbial communities, metagenomic sequencing has emerged as a powerful tool for elucidating the functionalities and interactions of diverse organisms. This burgeoning market is marked by the presence of several key players focused on innovation, scalability, and integration of cutting-edge sequencing technologies. Given the diverse applications of metagenomic sequencing in areas like environmental monitoring, agriculture, and clinical diagnostics, companies are vying for a significant share of the market by developing novel platforms and establishing strategic partnerships. These dynamics contribute to a competitive environment where research and development play a critical role in staying ahead of the curve and meeting the evolving demands of the healthcare landscape. Illumina stands out prominently in the US Metagenomic Sequencing Market, leveraging its robust technology and innovative solutions to bolster its market presence. This company has established itself as a leading force in the field of sequencing by providing high-throughput, scalable, and cost-effective solutions that cater to a wide array of applications in metagenomics. Illumina's strengths lie in its extensive portfolio of sequencers and comprehensive analysis software, which are critical for researchers aiming to generate high-quality data from complex biological samples. Additionally, the company has invested significantly in advancing its technology, focusing on enhancing accuracy and throughput while reducing costs, which positions it well against emerging competitors. Illumina's strategic partnerships and collaborations with academic institutions and research organizations also strengthen its influence within the market, reinforcing its reputation as a pioneer in metagenomic sequencing. BioRad Laboratories also plays a vital role in the US Metagenomic Sequencing Market, offering a diverse range of products and services that complement metagenomic research. The company's portfolio includes advanced reagents, instruments, and software solutions tailored to the needs of researchers engaged in microbial genomics and microbiome studies. BioRad's strengths lie in its commitment to delivering high-quality products that facilitate accurate and efficient data generation. The company's established market presence is bolstered by its strong relationships with academic and commercial research institutions, enabling collaborative ventures that enhance product development and innovation. Furthermore, BioRad's strategic mergers and acquisitions have expanded its capabilities within the life sciences sector, allowing it to integrate complementary technologies and broaden its portfolio. This strategic approach not only strengthens BioRad's position in the metagenomic sequencing market but also affirms its commitment to advancing scientific research and discovery in the US. ### **Key Companies in the US Metagenomic Sequencing Market Include** ### **US Metagenomic Sequencing Market Industry Developments** The US Metagenomic Sequencing Market has recently seen significant developments with companies like Illumina and Thermo Fisher Scientific advancing their product offerings aimed at enhancing genomic research, particularly in areas like environmental and clinical microbiology. In September 2023, Illumina announced the launch of its latest sequencing platform designed to streamline workflows, which has garnered attention in the research community. Growth in market valuation for companies involved in metagenomic sequencing, including BioRad Laboratories and Agilent Technologies, reflects a rising demand for innovative diagnostic tools amid increasing emphasis on personalized medicine. Additionally, in August 2023, F. Hoffmann-La Roche expanded its genomic capabilities through the acquisition of a key technology firm, further consolidating its position in the market. Current affairs also highlight collaborations among companies such as Oxford Nanopore Technologies and Genomatix to enhance data analysis techniques in metagenomic studies. Over the past few years, investments in research by Merck KGaA and Qiagen have driven advancements in metagenomic technologies, with the US government advocating for increased funding for genomic research initiatives. This momentum indicates a future ripe with potential for advancements in metagenomic sequencing in the US market. ## **US Metagenomic Sequencing Market Segmentation Insights** ### **Metagenomic Sequencing Market Product & Service****Outlook** ### **Metagenomic Sequencing Market Technology****Outlook** ## Market Drivers ### Advancements in Bioinformatics Tools The metagenomic sequencing market is significantly impacted by advancements in bioinformatics tools that facilitate data analysis and interpretation. As sequencing technologies generate vast amounts of data, the need for sophisticated analytical tools becomes paramount. Enhanced bioinformatics capabilities enable researchers to process and analyze complex metagenomic datasets more efficiently, leading to more accurate insights into microbial communities. In the US, the bioinformatics market is expected to grow to approximately $10 billion by 2025, driven by the increasing demand for data-driven decision-making in various sectors, including healthcare and environmental science. This driver underscores the importance of integrating advanced bioinformatics solutions into the metagenomic sequencing market, as they enhance the overall utility and applicability of sequencing data. ### Rising Demand for Personalized Medicine The metagenomic sequencing market is experiencing a notable surge in demand for personalized medicine. As healthcare shifts towards tailored treatments, the ability to analyze individual microbiomes becomes crucial. This trend is driven by advancements in sequencing technologies that allow for more precise and comprehensive analysis of microbial communities. In the US, the market for personalized medicine is projected to reach approximately $350 billion by 2025, indicating a robust growth trajectory. The integration of metagenomic sequencing into clinical practices enhances the understanding of patient-specific responses to therapies, thereby improving treatment outcomes. Consequently, this driver is pivotal in shaping the metagenomic sequencing market, as healthcare providers increasingly rely on detailed microbial insights to inform their clinical decisions. ### Growing Interest in Environmental Monitoring The metagenomic sequencing market is witnessing a growing interest in environmental monitoring, particularly in assessing microbial diversity and ecosystem health. As environmental concerns escalate, there is an increasing emphasis on understanding the role of microorganisms in various ecosystems. Metagenomic sequencing provides a powerful tool for monitoring microbial communities in soil, water, and air, enabling researchers to track changes in biodiversity and detect pollutants. In the US, the environmental monitoring market is projected to reach $20 billion by 2026, with a significant portion attributed to microbial analysis. This driver highlights the potential of metagenomic sequencing to contribute to environmental sustainability efforts, as stakeholders seek to leverage microbial insights for better management of natural resources. ### Increased Collaboration Between Academia and Industry The metagenomic sequencing market is benefiting from increased collaboration between academia and industry, fostering innovation and accelerating research. Partnerships between academic institutions and biotechnology companies are becoming more common, as they seek to leverage each other's strengths in research and development. This collaboration is particularly evident in the development of novel sequencing technologies and applications. In the US, funding for academic-industry partnerships has seen a rise, with federal grants supporting collaborative projects aimed at advancing metagenomic research. This driver is likely to enhance the metagenomic sequencing market by facilitating the translation of research findings into practical applications, ultimately leading to improved products and services in the field. ### Expansion of Applications in Infectious Disease Research The metagenomic sequencing market is significantly influenced by the expansion of applications in infectious disease research. With the increasing prevalence of antibiotic-resistant pathogens, there is a pressing need for innovative diagnostic tools. Metagenomic sequencing offers a comprehensive approach to identify and characterize pathogens directly from clinical samples, facilitating timely and accurate diagnoses. In the US, the market for infectious disease diagnostics is expected to grow at a CAGR of around 8% through 2025. This growth is likely to be fueled by the rising incidence of infectious diseases and the need for rapid identification methods. As researchers and clinicians adopt metagenomic sequencing for its ability to provide insights into complex microbial communities, this driver is expected to play a crucial role in the market's evolution. ## Future Outlook The [Metagenomic Sequencing Market](https://www.marketresearchfuture.com/reports/metagenomic-sequencing-market-5598) is projected to grow at a 14.99% CAGR from 2025 to 2035, driven by advancements in technology, increasing demand for personalized medicine, and rising applications in environmental monitoring. **New opportunities:** - Development of portable metagenomic sequencing devices for field research. Partnerships with pharmaceutical companies for drug discovery applications. Expansion of bioinformatics services to enhance data analysis capabilities. By 2035, the metagenomic sequencing market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product & Service: Reagents and Consumables (Largest) vs. Services (Fastest-Growing) Within the product and service segment of the US metagenomic sequencing market, reagents and consumables account for a significant share, primarily due to their essential role in sequencing processes. The demand for high-quality reagents is driven by the increase in applications across research, diagnostics, and therapeutics, thereby solidifying their position as the largest segment. Services, while smaller in share, are gaining traction rapidly as organizations seek expertise in data analysis and experimental design, reflecting their emerging importance in the market. Growth trends in the US metagenomic sequencing market reveal a shift towards automation and streamlined workflows, enhancing reagent usage efficiency. The expansion of services is propelled by an increasing need for specialized knowledge and support, which is vital for adapting new technologies in sequencing. This dynamic illustrates the evolving market landscape, wherein investment in reagents goes hand-in-hand with a growing reliance on services for successful implementation and exploitation of metagenomic technologies. Reagents and Consumables (Dominant) vs. Services (Emerging) Reagents and consumables are the backbone of the US metagenomic sequencing market, providing essential materials required for accurate sequencing results. Their dominance stems from the ongoing advancements in sequencing technology, which require high-quality reagents that ensure reliable and reproducible data. In contrast, services represent an emerging market segment, characterized by a growing demand for analytical support and bioinformatic expertise. As organizations become more data-driven, the necessity for specialized services that aid in data interpretation, experiments, and overall sequencing strategies will continue to rise. This creates a diverse ecosystem where dominant providers of reagents partner with emerging service providers to further enhance the efficiency and accessibility of metagenomic sequencing. ### By Technology: Shotgun Metagenomic Sequencing (Largest) vs. 16s rRNA Sequencing (Fastest-Growing) In the US metagenomic sequencing market, Shotgun Metagenomic Sequencing holds a significant portion of the market share, positioning itself as a leading technology. Its capability to provide comprehensive insights into microbial communities has made it a preferred choice among researchers. On the other hand, 16s rRNA Sequencing, while holding a smaller share, shows remarkable growth trends driven by increasing demand for innovative genetic analysis methods. The growth of the 16s rRNA Sequencing segment is fueled by advancements in sequencing technologies and a rising emphasis on understanding microbiome dynamics. This segment is witnessing a surge in applications across clinical diagnostics and environmental studies, further accelerating its expansion. Meanwhile, Shotgun Metagenomic Sequencing continues to dominate due to its extensive application range in diverse research fields, reinforcing its pivotal role in the market. Technology: Shotgun Metagenomic Sequencing (Dominant) vs. 16s rRNA Sequencing (Emerging) Shotgun Metagenomic Sequencing stands out as a dominant force in the US metagenomic sequencing market, offering unparalleled resolution in characterizing complex microbial ecosystems. Its broad applicability encompasses environmental monitoring, clinical diagnostics, and agricultural innovation, making it invaluable across numerous sectors. Conversely, 16s rRNA Sequencing is rapidly emerging, particularly in clinical microbiome research. This method boasts ease of use and cost-effectiveness, capturing increased interest from researchers. The distinct strengths of these two technologies cater to different market needs, with Shotgun Metagenomic Sequencing focusing on in-depth analysis, while 16s rRNA Sequencing appeals to those seeking targeted and efficient solutions. ## Competitive Benchmarking The metagenomic sequencing market is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for genomic data across various sectors, including healthcare, environmental monitoring, and agriculture. Key players such as Illumina (US), Thermo Fisher Scientific (US), and BGI Genomics (CN) are at the forefront, each adopting distinct strategies to enhance their market presence. Illumina (US) focuses on innovation through continuous development of next-generation sequencing technologies, while Thermo Fisher Scientific (US) emphasizes strategic partnerships to expand its product offerings and market reach. BGI Genomics (CN) leverages its cost-effective solutions to penetrate diverse markets, thereby intensifying competition among these major players. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with a mix of established players and emerging companies vying for market share. The collective influence of these key players shapes the competitive dynamics, as they continuously adapt to evolving customer needs and technological advancements. In October 2025, Illumina (US) announced a collaboration with a leading healthcare provider to integrate its sequencing technology into routine clinical diagnostics. This strategic move is likely to enhance patient outcomes by enabling more personalized treatment plans, thereby solidifying Illumina's position as a leader in the clinical genomics space. The partnership underscores the growing trend of integrating genomic data into healthcare, which may reshape treatment paradigms. In September 2025, Thermo Fisher Scientific (US) launched a new metagenomic sequencing platform designed to streamline workflows and reduce turnaround times for researchers. This innovation is expected to attract a broader customer base, particularly in academic and research institutions, as it addresses the increasing demand for rapid and reliable sequencing solutions. The launch reflects Thermo Fisher's commitment to maintaining its competitive edge through technological advancements. In August 2025, BGI Genomics (CN) expanded its operations in the US by establishing a new research facility focused on environmental metagenomics. This strategic expansion is indicative of BGI's intent to capitalize on the growing interest in environmental applications of metagenomics, potentially positioning the company as a key player in this niche market. The move may also enhance collaboration with local research institutions, fostering innovation in environmental monitoring. As of November 2025, current competitive trends in the metagenomic sequencing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into sequencing processes. Strategic alliances among key players are increasingly shaping the landscape, facilitating knowledge sharing and resource optimization. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the growing demands of diverse sectors. ## Recent News & Developments The US Metagenomic Sequencing Market has recently seen significant developments with companies like Illumina and Thermo Fisher Scientific advancing their product offerings aimed at enhancing genomic research, particularly in areas like environmental and clinical microbiology. In September 2023, Illumina announced the launch of its latest sequencing platform designed to streamline workflows, which has garnered attention in the research community. Growth in market valuation for companies involved in metagenomic sequencing, including BioRad Laboratories and Agilent Technologies, reflects a rising demand for innovative diagnostic tools amid increasing emphasis on personalized medicine. Additionally, in August 2023, F. Hoffmann-La Roche expanded its genomic capabilities through the acquisition of a key technology firm, further consolidating its position in the market. Current affairs also highlight collaborations among companies such as Oxford Nanopore Technologies and Genomatix to enhance data analysis techniques in metagenomic studies. Over the past few years, investments in research by Merck KGaA and Qiagen have driven advancements in metagenomic technologies, with the US government advocating for increased funding for genomic research initiatives. This momentum indicates a future ripe with potential for advancements in metagenomic sequencing in the US market. ## Report Scope | MARKET SIZE 2024 | 163.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 187.66(USD Million) | | MARKET SIZE 2035 | 758.53(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.99% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), BGI Genomics (CN), Qiagen (DE), Roche (CH), PerkinElmer (US), Agilent Technologies (US), Oxford Nanopore Technologies (GB) | | Segments Covered | Product & Service, Technology | | Key Market Opportunities | Advancements in bioinformatics tools enhance data analysis capabilities in the metagenomic sequencing market. | | Key Market Dynamics | Technological advancements drive innovation and competition in the metagenomic sequencing market, enhancing research capabilities and applications. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US metagenomic sequencing market in 2024?** A: The market valuation was $163.2 Million in 2024. **Q: What is the projected market valuation for the US metagenomic sequencing market by 2035?** A: The projected valuation for 2035 is $758.53 Million. **Q: What is the expected CAGR for the US metagenomic sequencing market during the forecast period 2025 - 2035?** A: The expected CAGR is 14.99% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the US metagenomic sequencing market?** A: Key players include Illumina, Thermo Fisher Scientific, BGI Genomics, Qiagen, Roche, PerkinElmer, Agilent Technologies, and Oxford Nanopore Technologies. **Q: What are the main product and service segments in the US metagenomic sequencing market?** A: Main segments include Reagents and Consumables, Instruments, and Services. **Q: What was the valuation of the Reagents and Consumables segment in 2024?** A: The Reagents and Consumables segment was valued at $65.0 Million in 2024. **Q: How much is the Whole Genome Sequencing and De Novo Assembly segment projected to be worth by 2035?** A: This segment is projected to reach $250.0 Million by 2035. **Q: What technologies are driving growth in the US metagenomic sequencing market?** A: Key technologies include Shotgun Metagenomic Sequencing, 16s rRNA Sequencing, Whole Genome Sequencing and De Novo Assembly, and Metatranscriptomic. **Q: What was the market size for Shotgun Metagenomic Sequencing in 2024?** A: The market size for Shotgun Metagenomic Sequencing was $40.0 Million in 2024. **Q: What is the projected growth for the Metatranscriptomic segment by 2035?** A: The Metatranscriptomic segment is projected to grow to $188.53 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-metagenomic-sequencing-market-19979*